Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Forecast 2025-2034

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Forecast Report Coverage

Expert Market Research's “Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of human immunodeficiency virus type 1 (HIV-1) infection. It projects the future incidence and prevalence rates of human immunodeficiency virus type 1 (HIV-1) infection across various populations. The study covers age, gender, and type as major determinants of the human immunodeficiency virus type 1 (HIV-1) infection-affected population. The report highlights patterns in the prevalence of human immunodeficiency virus type 1 (HIV-1) infection over time and projects future trends based on multiple variables.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection Disease Overview

Human immunodeficiency virus type 1 (HIV-1) infection is a viral infection that targets the immune system, leading to progressive immune dysfunction. Untreated HIV-1 can subsequently result in acquired immunodeficiency syndrome (AIDS). HIV type 1 is primarily transmitted through unprotected sexual contact, sharing of contaminated needles, and from mother to child during pregnancy, among others. The clinical progression of the infection is observed in three stages: acute infection, chronic infection, and AIDS. Early symptoms often include fever, flu-like signs, and fatigue.

Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Treatment Overview

Antiretroviral therapy (ART), which includes a combination of medications that work by suppressing the replication of the virus, is primarily used for the treatment of HIV-1 infection. Antiretroviral therapy helps in reducing the viral load to undetectable levels and prevents disease progression to AIDs. This treatment typically consists of a combination of at least three antiretroviral medications from different drug classes. Combination therapy or single-pill regimens are increasingly becoming popular as they combine multiple drugs into a single daily pill and improve adherence.

Epidemiology

The human immunodeficiency virus type 1 (HIV-1) infection epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for human immunodeficiency virus type 1 (HIV-1) infection by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for human immunodeficiency virus type 1 (HIV-1) infection and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Human immunodeficiency virus type 1 (HIV-1) represents a broad spectrum of subtypes and recombinant forms. Subtype C HIV-1 (C-HIV) is considered the most prevalent subtype worldwide, accounting for 46% of all infections and showing predominance in India, Southern Africa, and Ethiopia.
• HIV-1 is classified into four groups: M, N, O, and P. Group M includes nine subtypes or clades, with the C, B, and A reported as the main subtypes that account for about 70% of HIV-1 cases worldwide.
• As per a 2022 review article published in the Frontiers in Immunology, out of 38 million individuals affected with human immunodeficiency virus in 2020, 52% of the patient population was female.
• The WHO African Region is reported as the most severely affected area, with around 3.4% or 1 in 30 adults affected by HIV.

Country-wise Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology

The human immunodeficiency virus type 1 (HIV-1) infection epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of human immunodeficiency virus type 1 (HIV-1) infection varies between countries, influenced by differences in healthcare systems, transmission patterns, population factors, and access to prevention and treatment. According to the Centers for Disease Control and Prevention (CDC), approximately 1.1 million individuals were diagnosed with HIV in the United States in 2022, out of which 596,044 individuals (54%) were aged 50 years and above.

Country Specific Stats:

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of human immunodeficiency virus type 1 (HIV-1) infection based on several factors.
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of human immunodeficiency virus type 1 (HIV-1) infection are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of human immunodeficiency virus type 1 (HIV-1) infection epidemiology in the 8 major markets?
• What will be the total number of patients with human immunodeficiency virus type 1 (HIV-1) infection across the 8 major markets during the forecast period?
• What was the country-wise prevalence of human immunodeficiency virus type 1 (HIV-1) Infection in the 8 major markets in the historical period?
• Which country will have the highest number of human immunodeficiency virus type 1 (HIV-1) infection patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of human immunodeficiency virus type 1 (HIV-1) infection during the forecast period of 2025-2034?
• What are the currently available treatments for human immunodeficiency virus type 1 (HIV-1) infection?
• What are the disease risks, signs, symptoms, and unmet needs of human immunodeficiency virus type 1 (HIV-1) infection?

Related Reports

Human Immunodeficiency Virus (HIV1) Infection Market

Human Immunodeficiency Virus (HIV 1) Infection Drug Pipeline